Search results for "Nous"

showing 10 items of 2193 documents

Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late ch…

2007

The introduction of Imatinib (IM) has significantly altered the treatment for CML, although only limited follow-up results are available. As failure of Interferon-alpha had been associated with poor prognosis and results of IM-treatment in this patient group may allow earlier estimation of long-term benefits for early chronic phase patients. Therefore we prospectively analyzed the quality and duration of remissions and the rate of BCR-ABL resistance mutations occurring in patients treated with IM, if they were intolerant or refractory to interferon. Fifty-nine patients were included and median follow up is 4.75 years. Haematologic remission rate was 92% and 62% of patients achieved at least…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classAntineoplastic AgentsBiologyGastroenterologyTyrosine-kinase inhibitorDisease-Free SurvivalPiperazinesMedian follow-upInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansProtein Kinase InhibitorsSurvival analysisAgedRetrospective StudiesHematologyImatinibHematologyMiddle Agedmedicine.diseaseSurvival AnalysisLeukemiaImatinib mesylatePyrimidinesImmunologyBenzamidesImatinib MesylateFemaleChronic myelogenous leukemiamedicine.drugAmerican journal of hematology
researchProduct

Three-year European follow-up of endovenous radiofrequency-powered segmental thermal ablation of the great saphenous vein with or without treatment o…

2011

BackgroundRadiofrequency segmental thermal ablation (RSTA) has become a commonly used technology for occlusion of incompetent great saphenous veins (GSVs). Midterm results and data on clinical parameters are still lacking.MethodsA prospective multicenteral trial monitored 295 RSTA-treated GSVs for 36 months. Clinical control visits included flow and reflux analysis by duplex ultrasound imaging and assessment of clinical parameters according to the CEAP classification and Venous Clinical Severity Score (VCSS).ResultsA total of 256 of 295 treated GSVs (86.4%) were available for 36 months of follow-up. At 36 months, Kaplan-Meier survival analysis showed the probability of occlusion was 92.6% a…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.medical_treatmentPainKaplan-Meier EstimateRisk AssessmentSeverity of Illness IndexVaricose VeinsYoung AdultPredictive Value of TestsRisk FactorsOcclusionHumansPain ManagementMedicineSaphenous VeinProspective StudiesVeinProspective cohort studyAgedPain MeasurementUltrasonography Doppler DuplexChi-Square Distributionbusiness.industryVascular diseaseEndovascular ProceduresGreat saphenous veinRefluxMiddle Agedmedicine.diseaseAblationSurgeryEuropeTreatment Outcomemedicine.anatomical_structureRegional Blood FlowPredictive value of testsCatheter AblationFemaleSurgeryCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesJournal of Vascular Surgery
researchProduct

A two-cohort feasibility study on polyglycolic acid yarn implantation for abolition of saphenous vein reflux

2017

The objective of this study was to evaluate the feasibility and safety of a polyglycolic acid (PGA) yarn implant for nonthermal ablation of saphenous vein reflux.In two consecutive cohort studies (TAHOE I and TAHOE II), the feasibility of abolition of great saphenous vein (GSV) reflux by implantation of a PGA yarn was tested under ultrasound guidance in 51 and 30 patients, respectively. The use of tumescent local anesthesia was not required. Graduated compression stockings and thrombosis prophylaxis with low-molecular-weight heparin were used for 2 weeks after intervention in the first study only.Of 81 enrolled patients, 77 (95%) were available at 6-month follow-up. Complete occlusion of th…

AdultMalemedicine.medical_specialtyTime FactorsBiocompatible MaterialsKaplan-Meier Estimate030204 cardiovascular system & hematologyVaricose Ulcer03 medical and health sciences0302 clinical medicineFibrinolytic AgentsAbsorbable ImplantsOcclusionmedicineHumansSaphenous VeinLocal anesthesia030212 general & internal medicineVeinUltrasonography InterventionalAgedRetrospective StudiesUltrasonography Doppler DuplexWound Healingbusiness.industryDominican RepublicEndovascular ProceduresGreat saphenous veinRefluxRetrospective cohort studyMiddle Agedmedicine.diseaseThrombosisConfidence intervalSurgeryEuropeTreatment Outcomemedicine.anatomical_structureVenous InsufficiencyFeasibility StudiesFemaleSurgeryCardiology and Cardiovascular MedicinebusinessPolyglycolic AcidStockings CompressionJournal of Vascular Surgery: Venous and Lymphatic Disorders
researchProduct

Relationship between ACE-DD polymorphism and diastolic performance in healthy subjects.

2004

Background—The ACE-D allele has been associated with cardiovascular disease. The study evaluates the relationship between the ACE-ID genotypes and diastolic function in healthy subjects after 6 years of follow-up. Methods—Two hundred and seventy-five healthy volunteers aged 25–55 years had normal physical examination, 12-lead ECG, acceptable echocardiographic windows and echocardiogram at entry. Venous blood was drawn for DNA analysis. Results—Two hundred and forty-two subjects completed 6 years of follow-up. Three genetically distinct groups were obtained: ACE-DD group (n=71, 26F/45M, mean age 48±7 years); ACE-ID (n=115, 39F/76M, mean age 40±7 years); and ACE-II (n=56, 20F/36M, mean age 47…

AdultMalemedicine.medical_specialtyTime FactorsGenotypeDiastolePhysical examinationPeptidyl-Dipeptidase ARisk AssessmentWhite PeopleCohort StudiesSex FactorsPolymorphism (computer science)DiastolePredictive Value of TestsReference ValuesInternal medicinemedicineHumansProspective StudiesProspective cohort studyAllelesProbabilityAnalysis of VariancePolymorphism Geneticmedicine.diagnostic_testbusiness.industryAge FactorsHemodynamicsVenous bloodMiddle AgedEchocardiography DopplerSurgeryPredictive value of testsMultivariate AnalysisCardiologyFemaleAnalysis of varianceCardiology and Cardiovascular MedicinebusinessCohort studyFollow-Up StudiesScandinavian cardiovascular journal : SCJ
researchProduct

Limb Ischemic Conditioning Induces Oxidative Stress Followed by a Correlated Increase of HIF-1α in Healthy Volunteers.

2019

Background Local and remote ischemic preconditioning has been used as a protective intervention against ischemia/reperfusion (I/R) damage in several preclinical and clinical studies. However, its physiological mechanisms are not completely known. I/R increases the production of reactive oxygen species, which also serve as messengers for a variety of functions. Hypoxia-inducible factor 1 alpha (HIF-1α) is probably the most important transcription factor mediator of hypoxic signaling. Objective We hypothesized that limb ischemic conditioning (LIC) induces a local oxidative/nitrosative stress and a correlated increase of HIF-1α plasma levels. Methods An observational, prospective, and single-c…

AdultMalemedicine.medical_specialtyTime FactorsIschemiaOxidative phosphorylation030204 cardiovascular system & hematologymedicine.disease_causeDinoprost030218 nuclear medicine & medical imagingUpper Extremity03 medical and health scienceschemistry.chemical_compoundYoung Adult0302 clinical medicineInternal medicineBlood plasmamedicineHumansProspective StudiesNitriteIschemic PreconditioningNitriteschemistry.chemical_classificationReactive oxygen speciesbusiness.industryGeneral MedicineVenous bloodmedicine.diseaseHypoxia-Inducible Factor 1 alpha SubunitHealthy VolunteersUp-RegulationOxidative StressEndocrinologychemistryNitrosative StressRegional Blood FlowSpainIschemic preconditioningSurgeryFemaleTherapeutic OcclusionCardiology and Cardiovascular MedicinebusinessOxidative stressBiomarkersAnnals of vascular surgery
researchProduct

[Inferior vena cava malformations and deep venous thrombosis].

2006

We carried out a prospective study of 116 patients under 50 years of age who had deep venous thrombosis of the lower extremities to determine whether the presence of congenital anomaly of the inferior vena cava (IVC) was a risk factor for the disease. All patients were investigated by Doppler echography. Some 37 patients who had iliac vein occlusion also underwent phlebography. In 10 patients in whom the IVC was difficult to image, magnetic resonance angiography or computerized axial tomography was carried out. In all patients, studies of antithrombin, protein C and protein S deficiency, factor V Leiden, prothrombin G20210A, antiphospholipid antibodies, and acquired risk factors were also p…

AdultMalemedicine.medical_specialtyTime FactorsPopliteal VeinFemoral veinVena Cava InferiorIliac VeinInferior vena cavaRecurrenceRisk FactorsmedicineFactor V LeidenConfidence IntervalsHumansProtein S deficiencyProspective StudiesVenous ThrombosisLegbusiness.industryAnticoagulantsUltrasonography DopplerGeneral MedicinePhlebographyFemoral VeinMiddle Agedmedicine.diseaseThrombosisVein occlusionSurgeryVenous thrombosisTreatment Outcomemedicine.veincardiovascular systemProthrombin G20210AFemaleRadiologybusinessTomography X-Ray ComputedMagnetic Resonance AngiographyFollow-Up StudiesRevista espanola de cardiologia
researchProduct

Lipoprotein(a) is not associated with venous thromboembolism risk.

2020

Objectives. Evidence from case-control studies as well as meta-analyses of these study designs suggest elevated lipoprotein(a) [Lp(a)] to be associated with an increased risk of venous thromboembolism (VTE). Prospective evidence on the association is limited, uncertain, and could be attributed to regression dilution bias. We aimed to assess the prospective association of Lp(a) with risk of VTE and correct for regression dilution. Design. We related plasma Lp(a) concentrations to the incidence of VTE in 2,180 men of the Kuopio Ischemic Heart Disease cohort study. Hazard ratios (HRs) (95% confidence intervals [CI]) were assessed and repeat measurements of Lp(a) at 4 and 11 years from baseline…

AdultMalemedicine.medical_specialtyTime FactorsPopulationRegression dilutionvenous thromboembolism030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicinecohort studyHumans030212 general & internal medicineregression dilutionProspective StudiesRisk factoreducationFinlandeducation.field_of_studybiologybusiness.industryIncidenceHazard ratioConfoundingLipoprotein(a)Venous ThromboembolismMiddle AgedPrognosisConfidence intervalrisk factorbiology.proteinCardiology and Cardiovascular MedicinebusinessBiomarkersCohort studyLipoprotein(a)Scandinavian cardiovascular journal : SCJ
researchProduct

Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol

2006

Objectives: to evaluate the clinical efficacy and the effects on the quality of life of Iloprost, a prostacyclin analogue, used, according to a new protocol, in patients with Raynaud’s phenomenon secondary to Systemic Sclerosis. Methods: in this randomized study we treated 30 patients with Iloprost given by intravenous infusion, at progressively increasing doses (starting from 0.5 ng/Kg/min up 2 ng/Kg/min) over a period of 6 hours a day for ten days in two consecutive weeks, with repeated cycles at regular intervals of three months for 18 months. The results were compared with those obtained in 30 other patients, who had received the same drug but with different posologic schemes. Results: …

AdultMalemedicine.medical_specialtyTime FactorsVasodilator AgentsSeverity of Illness IndexDrug Administration ScheduleSclerodermalaw.inventionRheumatologyRandomized controlled trialQuality of lifelawSeverity of illnessmedicineHumansPharmacology (medical)IloprostProspective StudiesDosingInfusions IntravenousProspective cohort studySystemic Sclerosis Raynaud's phenomenon Iloprost Quality of lifeScleroderma SystemicDose-Response Relationship DrugVascular diseasebusiness.industryRaynaud DiseaseMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeAnesthesiaQuality of LifeFemalebusinessIloprostmedicine.drugRheumatology
researchProduct

Protein Ingestion Prior to Strength Exercise Affects Blood Hormones and Metabolism

2005

HULMI, J. J., J. S. VOLEK, H. SELANNE, and A. A. MERO. Protein Ingestion Prior to Strength Exercise Affects Blood Hormones and Metabolism. Med. Sci. Sports Exerc., Vol. 37, No. 11, pp. 1990 -1997, 2005. Purpose: The effects of protein consumption before strength training session on blood hormones, energy metabolites, RER, and excess postexercise oxygen consumption (EPOC) were examined. Methods: Ten resistance-trained young men consumed either a 25 g of whey and caseinate proteins (PROT) or a noncaloric placebo (P) in a liquid form 30 min before a heavy strength training session (STS) in a crossover design separated by at least 7 d. STS lasted 50 min and included 5 1 RM squats, 3 10 RM squat…

AdultMalemedicine.medical_specialtyTime FactorsWeight LiftingStrength trainingmedicine.medical_treatmentPhysical Therapy Sports Therapy and RehabilitationPhysical exercisePlacebosOxygen ConsumptionInternal medicinemedicineHumansInsulinIngestionTestosteroneOrthopedics and Sports MedicinePancreatic hormoneCross-Over StudiesHuman Growth HormoneChemistryInsulinFatty AcidsVenous bloodMilk ProteinsCrossover studyWhey ProteinsEndocrinologyArea Under CurveDietary ProteinsOxidation-ReductionHormoneMedicine & Science in Sports & Exercise
researchProduct

Dose-Adjusted Thrombosis Prophylaxis in Trauma Surgery According to Levels of D-Dimer

2000

In 234 trauma surgery patients, thrombosis prophylaxis with Nadroparin-Calcium low-molecular-weight heparin (LMWH) was adjusted according to levels of D-Dimer. Basic prophylaxis was 2,850 IU per day. If D-Dimer concentrations rose above 2 mg/L after the fourth postoperative (p.o.) day, LMWH was administered twice a day. Color Doppler ultrasound was performed between the fifth and seventh p.o. days. Patients were divided into a high-risk (group 1: hip, femur, or knee replacement surgery, n=102) and a moderate-risk group (group 2: other surgery of the knee, tibia, fibula, or foot, n=132). Group 1 showed significantly higher D-Dimer levels than group 2 (p0.001). Measurement of D-Dimer on days …

AdultMalemedicine.medical_specialtyTime Factorsmedicine.drug_classmedicine.medical_treatmentDeep veinAntithrombin IIIKnee replacementLow molecular weight heparinSensitivity and SpecificityFibrin Fibrinogen Degradation ProductsFractures BoneRisk FactorsAntifibrinolytic agentD-dimerHumansMedicineAgedAged 80 and overVenous Thrombosisbusiness.industryAnticoagulantNadroparinHematologyMiddle Agedmedicine.diseaseAntifibrinolytic AgentsSurgeryVenous thrombosismedicine.anatomical_structureAnesthesiaWounds and InjuriesFemalebusinessTrauma surgeryBiomarkersLeg InjuriesPeptide HydrolasesThrombosis Research
researchProduct